Skip Nav Destination
Issues
15 March 2007
-
Cover Image
Cover Image
U87MG glioma cells expressing the de2-7 EGFR (or EGFRvIII) were transiently transfected with the lysosomal marker lgp-120 tagged with GFP (green staining). After transfection, cells were incubated with mAb 806-cy3 at 4°C (red staining), before induction of internalization by incubating at 37°C for 0 (top left), 30 (top right), 60 (bottom left) and 120 (bottom right) minutes. Colocalization of mAb 806-Cy3 and lgp-120-GFP in the lysosomes can be clearly observed at 60 and 120 minutes (yellow staining). For further details, please see Johns et al. on page 1911 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
CCR Practice of Translational Oncology
Molecular Pathways
CCR Focus
Human Cancer Biology
Identification and Prognostic Significance of an Epithelial-Mesenchymal Transition Expression Profile in Human Bladder Tumors
Egbert Baumgart; Michael S. Cohen; Brasil Silva Neto; Micah A. Jacobs; Chad Wotkowicz; Kimberly M. Rieger-Christ; Andreia Biolo; Ron Zeheb; Massimo Loda; John A. Libertino; Ian C. Summerhayes
Distinct Mitotic Segregation Errors Mediate Chromosomal Instability in Aggressive Urothelial Cancers
Yuesheng Jin; Ylva Stewénius; David Lindgren; Attila Frigyesi; Olga Calcagnile; Tord Jonson; Anna Edqvist; Nina Larsson; Lena Maria Lundberg; Gunilla Chebil; Fredrik Liedberg; Sigurdur Gudjonsson; Wiking Månsson; Mattias Höglund; David Gisselsson
Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression
John Ian Risinger; Gadisetti V.R. Chandramouli; G. Larry Maxwell; Mary Custer; Svetlana Pack; Dmitri Loukinov; Olga Aprelikova; Tracy Litzi; David S. Schrump; Susan K. Murphy; Andrew Berchuck; Victor Lobanenkov; J. Carl Barrett
Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage
Morgan Rouprêt; Vincent Hupertan; David R. Yates; James W.F. Catto; Ishtiaq Rehman; Mark Meuth; Sylvie Ricci; Roger Lacave; Géraldine Cancel-Tassin; Alexandre de la Taille; François Rozet; Xavier Cathelineau; Guy Vallancien; Freddie C. Hamdy; Olivier Cussenot
Imaging, Diagnosis, Prognosis
Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma
Amy E. Krambeck; Haidong Dong; R. Houston Thompson; Susan M. Kuntz; Christine M. Lohse; Bradley C. Leibovich; Michael L. Blute; Thomas J. Sebo; John C. Cheville; Alexander S. Parker; Eugene D. Kwon
Cancer Therapy: Clinical
Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers
Ramesh K. Ramanathan; Merrill J. Egorin; Julie L. Eiseman; Suresh Ramalingam; David Friedland; Sanjiv S. Agarwala; S. Percy Ivy; Douglas M. Potter; Gurkamal Chatta; Eleanor G. Zuhowski; Ronald G. Stoller; Cynthia Naret; Jianxia Guo; Chandra P. Belani
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
David B. Solit; S. Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J. Morris; Susan F. Slovin; W. Kevin Kelly; Anthony DeLaCruz; Tracy Curley; Glenn Heller; Steven Larson; Lawrence Schwartz; Merrill J. Egorin; Neal Rosen; Howard I. Scher
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study
Rochelle Bagatell; Lia Gore; Merrill J. Egorin; Richard Ho; Glenn Heller; Nichole Boucher; Eleanor G. Zuhowski; James A. Whitlock; Stephen P. Hunger; Aru Narendran; Howard M. Katzenstein; Robert J. Arceci; Jessica Boklan; Cynthia E. Herzog; Luke Whitesell; S. Percy Ivy; Tanya M. Trippett
A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study
Brenda J. Weigel; Susan M. Blaney; Joel M. Reid; Stephanie L. Safgren; Rochelle Bagatell; John Kersey; Joseph P. Neglia; S. Percy Ivy; Ashish M. Ingle; Luke Whitesell; Richard J. Gilbertson; Mark Krailo; Matthew Ames; Peter C. Adamson
Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
Bernard Escudier; Nathalie Lassau; Eric Angevin; Jean Charles Soria; Linda Chami; Michele Lamuraglia; Eric Zafarana; Veronique Landreau; Brian Schwartz; Eric Brendel; Jean-Pierre Armand; Caroline Robert
A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer
Denis C. Talbot; Joachim von Pawel; Emma Cattell; S. Murray Yule; Claire Johnston; Anthe S. Zandvliet; Alwin D.R. Huitema; Chris J. Norbury; Paul Ellis; Leon Bosquee; Martin Reck
Cancer Therapy: Preclinical
Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer
Jordan S. Fridman; Eian Caulder; Michael Hansbury; Xiangdong Liu; Genjie Yang; Qian Wang; Yvonne Lo; Bin-Bing Zhou; Maxwell Pan; Sufi M. Thomas; Jennifer R. Grandis; Jincong Zhuo; Wenqing Yao; Robert C. Newton; Steven M. Friedman; Peggy A. Scherle; Kris Vaddi
The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization
Terrance G. Johns; Rushika M. Perera; Sonja C. Vernes; Angela A. Vitali; Diana X. Cao; Webster K. Cavenee; Andrew M. Scott; Frank B. Furnari
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.